Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response.

被引：0
|
作者：
Rifkin, Robert M. [1 ,2 ]
Spitzer, Gary [1 ,3 ]
Greenspan, Andrew [1 ,4 ]
Schwerkoske, John F. [1 ,5 ]
Mandanas, Romeo A. [6 ]
Stephenson, Joe [1 ,3 ]
Kannarkat, George T. [1 ,7 ]
Zhan, Feng [1 ]
Asmar, Lina [1 ]
Beveridge, Roy [1 ,7 ]
机构：
[1] US Oncol Res Inc, Houston, TX USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Canc Ctr Carolinas, Greenville, SC USA
[4] Cent Indiana Canc Ctr, Indianapolis, IN USA
[5] Minnesota Oncol Hematol, St Paul, MN USA
[6] Canc Care Associates W, Oklahoma City, OK USA
[7] Fairfax No Virginia Hematol Oncol, Fairfax, VA USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：960 / 960
页数：1
相关论文
共 50 条
  • [31] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    Dunia, D. M.
    Dolores, M.
    Dolores, S.
    Nuria, G.
    Miguel, D.
    Jaime, A.
    Helga, G.
    Alejandro, V.
    Sonia, H.
    Blanca, P.
    HAEMATOLOGICA, 2016, 101 : 862 - 862
  • [32] High-dose thiotepa, melphalan and carboplatin followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - a retrospective evaluation
    Demirer, T
    Soydan, E
    Fen, T
    Ilhan, O
    Ayli, M
    Arat, M
    Ozcan, M
    Gunel, N
    Arslan, O
    Genc, Y
    Uysal, A
    Haznedar, R
    Buyukberber, S
    Gurman, G
    Ustaer, N
    Hazar, B
    Ozet, G
    Akan, H
    BONE MARROW TRANSPLANTATION, 2004, 33 : S250 - S250
  • [33] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    de Miguel, D.
    Morales, D.
    San Roman, I.
    Golbano, N.
    Diaz, M.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    PInedo, B.
    HAEMATOLOGICA, 2012, 97 : 622 - 622
  • [34] High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)
    Sterrenberg, Danielle
    Stiff, Patrick J.
    Parthasarathy, Mala
    Go, Aileen
    Smith, Scott E.
    Rodriguez, Tulio E.
    BLOOD, 2013, 122 (21)
  • [35] A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma
    Mark, Tomer M.
    Guarneii, Danielle
    Forsberg, Peter
    Rossi, Adriana
    Pearse, Roger
    Perry, Arthur
    Pekle, Karen
    Tegnestam, Linda
    Greenberg, June
    Shore, Tsiporah
    Gergis, Usama
    Mayer, Sebastian
    Van Besien, Koen
    Ely, Scott
    Jayabalan, David
    Sherbenou, Daniel
    Coleman, Morton
    Niesvizky, Ruben
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (06) : 930 - 937
  • [36] High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
    Cook, Gordon
    Williams, Cathy
    Brown, Julia M.
    Cairns, David A.
    Cavenagh, Jamie
    Snowden, John A.
    Ashcroft, A. John
    Fletcher, Marie
    Parrish, Chris
    Yong, Kwee
    Cavet, Jim
    Hunter, Hanna
    Bird, Jenny M.
    Chalmers, Anna
    O'Connor, Sheila
    Drayson, Mark T.
    Morris, Treen C. M.
    LANCET ONCOLOGY, 2014, 15 (08): : 874 - 885
  • [37] High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency
    OF Ballester
    R Tummala
    WE Janssen
    KK Fields
    JW Hiemenz
    SC Goldstein
    JB Perkins
    DM Sullivan
    R Rosen
    R Sackstein
    P Zorsky
    R Saez
    GJ Elfenbein
    Bone Marrow Transplantation, 1997, 20 : 653 - 656
  • [38] High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency
    Ballester, OF
    Tummala, R
    Janssen, WE
    Fields, KK
    Hiemenz, JW
    Goldstein, SC
    Perkins, JB
    Sullivan, DM
    Rosen, R
    Sackstein, R
    Zorsky, P
    Saez, R
    Elfenbein, GJ
    BONE MARROW TRANSPLANTATION, 1997, 20 (08) : 653 - 656
  • [39] High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
    E Nadal
    E Giné
    J Bladé
    J Esteve
    L Rosiñol
    F Fernández-Avilés
    P Marin
    C Martinez
    M Rovira
    A Urbano-Ispizua
    E Carreras
    E Montserrat
    Bone Marrow Transplantation, 2004, 33 : 61 - 64
  • [40] High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma:: predictors of complete remission
    Nadal, E
    Giné, E
    Bladé, J
    Esteve, J
    Rosiñol, L
    Fernández-Avilés, F
    Marin, P
    Martinez, C
    Rovira, M
    Urbano-Ispizua, A
    Carreras, E
    Montserrat, E
    BONE MARROW TRANSPLANTATION, 2004, 33 (01) : 61 - 64
12345